SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (œR2) Evorpacept plus R2 was well tolerated with a safety profile...
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
ALX Oncology Announces Evorpacept Clinical Abstracts Accepted for Presentation
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (œALX Oncology or œthe Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (œALX Oncology or the œCompany) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (œALX Oncology or the œCompany) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...